

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/714,591	11/14/2003	Janakiraman Ramachandran	GANG-006	3234
24353	7590 07/20/2006		EXAMINER	
BOZICEVIC, FIELD & FRANCIS LLP			KINSEY, NICOLE	
1900 UNIVERSITY AVENUE SUITE 200			ART UNIT	PAPER NUMBER
EAST PALO ALTO, CA 94303			1648	

DATE MAILED: 07/20/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Commons	10/714,591	RAMACHANDRAN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Nicole E. Kinsey, Ph.D.	1648				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirr rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
	action is non-final.					
<del>=</del>	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>1-16</u> is/are pending in the application.						
, , , , , , , , , , , , , , , , , , , ,	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.	· · · · · · · · · · · · · · · · · · ·					
7) Claim(s) is/are objected to.	· · · · · · · · · · · · · · · · · · ·					
8) Claim(s) <u>1-16</u> are subject to restriction and/or e	election requirement.					
Application Papers	1					
	_					
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Trip The bath of declaration is objected to by the Ex	aminer. Note the attached Office	Action of form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:						
_ · · · ·	2. Certified copies of the priority documents have been received in Application No					
	3. Copies of the certified copies of the priority documents have been received in this National Stage					
	application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) D Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date					
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date  5) Notice of Informal Patent Application (PTO-152)  6) Other:						
Paper No(s)/Mail Date						

Art Unit: 1648

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - Claims 1-9, drawn to a method for inhibiting growth of bacteria, classified in class 435, subclass 235.1.
  - II. Claims 10-13, drawn to a pharmaceutical composition comprising a holin-modified bacteriophage, classified in class 435, subclass 235.1.
  - Claims 14-16, drawn to a method of making a holin-modified phage, classified in class 435, subclass 235.1.
- 2. The inventions are distinct, each from the other because of the following reasons:

Groups I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h).

In the instant case, the process for inhibiting growth of a bacterium can be practiced with another materially different product such as an antibiotic, and bacteriophages can be used in a materially different process such as constructing DNA libraries with phage cloning vectors.

Art Unit: 1648

In addition to their distinctness, searching the inventions of Groups I and II would impose a serious search burden. Even though Groups I and II are identically classified under U.S. Patent Classification guidelines, the search required for Group I is not required for Group II and vice versa. Thus, a separate search is required for each Group, which would impose a serious search burden on the Examiner. Therefore, because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02) resulting in a serious search burden on the Examiner, restriction for examination purposes as indicated is proper.

3. Groups I and III are directed to related subject matter (i.e., a holin-modified phage). The related inventions are distinct if the inventions as claimed do not overlap in scope, i.e., are mutually exclusive; the inventions as claimed are not obvious variants; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See MPEP § 806.05(j).

In the instant case, the method of Group I and the method of Group III do not overlap in scope (i.e., the outcome of the method of Group I has no effect on the outcome of the method of Group III). Further, the method of inhibiting bacterial growth is not an obvious variant of a method of making a holin-modified phage by virtue of the very different steps required to carry out each method. In addition, the methods have materially different designs, mode of operation, function or effect where the method of

Application/Control Number: 10/714,591

Art Unit: 1648

Group I results in inhibiting bacterial growth and the method of Group III results in production of a modified phage.

In addition to their distinctness, searching the inventions of Groups I and III would impose a serious search burden. Even though Groups I and III are identically classified under U.S. Patent Classification guidelines, the search required for Group I is not required for Group III and vice versa. Thus, a separate search is required for each Group, which would present a search burden on the Examiner. Therefore, because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

4. Groups II and III are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make another and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)).

In the instant case, the method of making a holin-modified phage as claimed is not specific for a holin-modified phage. The claimed method, i.e., contacting a bacterial production host with a phage where infection results in phage progeny, can be used to produce other types of bacteriophage, e.g., lambda phage.

In addition to their distinctness, searching the inventions of Groups II and III would impose a serious search burden. While Groups II and III can be identically classified under U.S. Patent Classification guidelines, to search them together would

Art Unit: 1648

present a search burden on the Examiner because the search required for Group II is not required for Group III and vice versa. Thus, a separate search is required for each Group, which would present a search burden on the Examiner. Therefore, because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

## Notice of Possible Rejoinder

5. The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

All claims directed a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP

Application/Control Number: 10/714,591

Page 6

Art Unit: 1648

§ 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder**. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

6. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Art Unit: 1648

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nicole E. Kinsey, Ph.D. whose telephone number is (571) 272-9943. The examiner can normally be reached on 8:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

BRUCE R. CAMPELL, PH.Ø SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600